Events & Presentations
Upcoming Events
More events are coming soon.
Past Events
Jan 16, 2025 at 9:00 AM PST
Helen Sabzevari, PhD, President and CEO of Precigen, presented at the 43rd Annual J.P. Morgan Healthcare Conference.
Nov 19, 2024
at 10:55 AM - 11:25 AM EST
Helen Sabzevari, PhD, President and CEO of Precigen, to participate in fireside chat on November 19, 2024 at the Stifel 2024 Healthcare Conference.
Oct 26 - Oct 27, 2024
Helen Sabzevari, PhD, President and CEO, Precigen to present "UltraCAR-T Platform: Revolutionizing the Field of CAR-T from Blood Draw to Infusion of Autologous, Multigenic Cell Therapy Overnight" on Saturday, October 26, 2024, from 13:30-13:50 GST.
Abu Dhabi, UAE
Oct 08, 2024 at 11:00 AM MDT
Helen Sabzevari, PhD, President and CEO of Precigen, to present a company overview presentation.
Phoenix, AZ
Sep 28, 2024
at 9:30 AM - 10:30 AM EDT
Clint T. Allen, MD, National Cancer Institute (NCI) surgical oncology acting branch chief and lead investigator for the PRGN-2012 clinical trial, will discuss the preclinical development and Phase 1/2 clinical study results of PRGN-2012, a gorilla adenovirus gene therapy designed to enhance human papillomavirus (HPV)-specific immune responses in adult patients with recurrent respiratory papillomatosis.
Miami Beach, FL
Sep 18, 2024
at 9:45 AM - 10:15 AM EDT
Helen Sabzevari, PhD, President and CEO of Precigen, to participate in a fireside chat at the 2024 Cantor Global Healthcare Conference in New York.
New York, NY
Aug 14, 2024 at 4:30 PM EDT
Precigen will host a conference call to discuss second quarter and first half 2024 financial results and provide a general business update. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.
Jun 03, 2024 at 6:00 PM CDT
Precigen webcast following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 31 - Jun 04, 2024
Abstract Selected for Late-Breaking Oral Presentation
- June 3, 2024 | 8:00 AM - 9:30 AM CT
PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients
Abstract: 6015 | Rapid Oral Abstract Session - Head and Neck Cancer
Abstracts Selected for Poster Presentation
- June 2, 2024 | 9:00 AM - 12:00 PM CT
Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer
Abstract: 6124 | Poster Session - Head and Neck Cancer - June 3, 2024 | 9:00 AM - 12:00 PM CT
A Phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer
Abstract 5623 | Poster Session - Gynecologic Cancer
Chicago, Illinois
May 15 - May 19, 2024
Precigen to participate in the 2024 COSM annual meeting taking place in Chicago from May 15 to May 19, 2024. On May 16 at 4:21 PM CT, Dr. Clint T. Allen, MD, Principal Investigator with the Section on Translational Tumor Immunology at the National Institutes of Health and a lead investigator for the PRGN-2012 clinical study, will present "Clinical Benefit following Adjuvant Therapeutic Vaccination with PRGN-2012 in Adult Patients with RRP."
Chicago, Illinois
May 14, 2024
Precigen first quarter 2024 financial results and business updates.
Apr 09 - Apr 11, 2024
Helen Sabzevari, PhD, President and CEO of Precigen, to participate in two events at the 2024 Alliance for Regenerative Medicine Cell and Gene Meeting on the Med. She will participate as a panelist on a panel titled "A Forecast on the 2024 CGTx Landscape" on Tuesday, April 9, 2024 at 5:15 PM CET and provide a company presentation on Wednesday, April 10, 2024 at 2:30 PM CET.
Rome, Italy
Mar 25, 2024 at 1:00 PM EDT
Hosted by Jennifer Kim, Biotechnology Analyst at Cantor Fitzgerald, the virtual fireside chat will include discussion of the investigational PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP). Participants will include Helen Sabzevari, PhD, President and CEO of Precigen, and Clint T. Allen, MD, Principal Investigator, Section on Translational Tumor Immunology at the National Institutes of Health (NIH), and a lead investigator for the PRGN-2012 clinical study. The call is available to institutional clients of Cantor Fitzgerald.
Mar 19, 2024 at 4:30 PM EDT
Precigen full year 2023 financial results and general business updates.
Mar 13 - Mar 16, 2024
Precigen participated in the Eurogin International Multidisciplinary HPV Congress taking place March 13-16 in Stockholm, Sweden.
Stockholm, Sweden